Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis
about
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) familyActivation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammationSelectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responsesThe role of pro-resolution lipid mediators in infectious diseaseResistance to melanoma metastases in mice selected for high acute inflammatory responseMechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxinsLipoxins in chronic inflammationResolution of inflammation: a new paradigm for the pathogenesis of periodontal diseasesOverexpression of apolipoprotein A1 in the lung abrogates fibrosis in experimental silicosisEndogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production.Lipoxin a(4) attenuates microvascular fluid leak during inflammationThe endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection.Regulation of the formyl peptide receptor 1 (FPR1) gene in primary human macrophagesImpact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetesA novel rat lipoxin A4 receptor that is conserved in structure and function.A role for lipoxin A₄ as an anti-inflammatory mediator in the human endometriumResolvins and protectins in inflammation resolution.Deletion of the aryl hydrocarbon receptor enhances the inflammatory response to Leishmania major infectionAspirin triggered lipid mediators: novel inhibitors of leucocyte traffickingApoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression.Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytesLipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases.Dihydroxyoctadecamonoenoate esters inhibit the neutrophil respiratory burst.Lipoxins in asthma: potential therapeutic mediators on bronchial inflammation?beta(2)-Adrenergic receptor-dependent sexual dimorphism for murine leukocyte migration.Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii.Antimicrobial peptide scolopendrasin VII, derived from the centipede Scolopendra subspinipes mutilans, stimulates macrophage chemotaxis via formyl peptide receptor 1.Therapeutic Targets for Management of Periodontitis and DiabetesAtherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediatorsThe use of rodent models to investigate host-bacteria interactions related to periodontal diseases.Anti-inflammatory and proresolving lipid mediators.A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction.Lipoxins: resolutionary road.Genetics of infectious diseases: hidden etiologies and common pathways.Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer.DNA sequence variation and regulation of genes involved in pathogenesis of pulmonary tuberculosis.Lipid mediators in immune dysfunction after severe inflammation.Resolution of inflammation: targeting GPCRs that interact with lipids and peptides.Fundamentals of and Critical Issues in Lipid Autacoid Medicine: A Review.
P2860
Q24652940-3E563B56-9C3B-49A4-AA2F-83BE708C36ECQ24676421-2200870D-10BD-4679-B31F-DDB88000DD10Q24685948-B888C0E2-3847-46A8-B8AB-BFFC7DA56B8EQ26863204-A6D41051-5524-49CD-B28D-2217B23EF0F1Q28175948-4C77B5EB-1674-441E-A326-382AC15BFC46Q28182535-01A2572C-3B34-456F-91DD-349122FB997FQ28196238-39FFC85A-7B3F-4B2D-A094-F0D46F7C71E1Q28206660-A5F7DE86-74C9-44CE-8E71-996E18CCF013Q28394219-DE052A10-F963-4E91-BFAA-05642BB693E6Q31134484-0DE6013E-40B3-4CC3-ABD2-5160B015E185Q33831917-CEE1B649-A11B-4B7F-9273-851A40B57BAAQ34160432-24FFD22F-5A3E-4BA4-A7DE-CCD5C8F60E7BQ34482353-F4A25A93-7857-479D-BAAB-04C3A36EA9BAQ34491175-57E402CE-FDDC-4D01-AB71-18B862F380C2Q34955621-01D95B10-933D-4E08-8353-D6B9118C2A04Q35045249-9410A6BE-162F-413D-B5BD-E1C903A6CA94Q35114951-15473AD1-BC65-46E5-A5E1-3CB7BCAAD12DQ35332873-E581EEC7-01CC-4D1A-9BA7-09958A40B555Q35565135-2F8ABE33-E725-41B8-9472-4C2DC2F2990AQ35577366-F980D99A-E589-4120-9CFC-9175159EE15BQ35633812-E82A4F01-555A-4527-8172-85850BEE6A40Q35734691-DE940EAC-3AA6-4946-A724-66DA76C9C345Q35747915-FEE5C54A-7446-47B0-BBA8-03911171C54EQ35865405-65813630-9769-4A78-9831-3CCDBB19BA7BQ35881906-54987281-4811-4B29-B5E5-DD36E7F760FCQ36013500-81F5A01E-37F9-40DA-8296-8A1DCFC1B105Q36015869-EF235A19-15A2-44AA-91AE-19208AFED609Q36078499-4F3AC706-8431-4721-9FDC-F6FAC6F1944CQ36863273-FDB2FBD2-C955-461D-A228-70D6E29B7963Q36879456-B02B23E5-05AB-4225-99A7-0045D5C12EC2Q37058550-CF421E47-9C7F-4A1B-B26B-DD950FE67BF1Q37071968-B672B78B-057E-43B5-B7F3-016001C8EAECQ37591768-16FF31DA-21E8-41F2-8067-19AB381FE7E5Q37604436-898F87F6-98B0-43F4-8AFC-41E4EFAB56C6Q37880890-DAC1CFEE-CC2C-41F6-AC20-49D8A0909C4FQ37947960-BF9C37A2-DEA4-4D95-B66C-9B85359CAD75Q37993616-CDF90641-CA07-40E6-8794-E547816A805DQ38165517-934F174D-CB59-4C8C-AFBA-8FFD966BB272Q38226022-280121E9-8475-4908-9B89-E1EE40BC323FQ38718096-0541540D-7E50-46FA-A8C6-0F7D8536E8D4
P2860
Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@ast
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@en
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@nl
type
label
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@ast
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@en
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@nl
prefLabel
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@ast
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@en
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@nl
P2093
P2860
P3181
P356
P1476
Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis
@en
P2093
C N Serhan
M Hachicha
N A Petasis
P2860
P304
P3181
P356
10.1084/JEM.189.12.1923
P407
P50
P577
1999-06-21T00:00:00Z